title: S100A1 gene transfer in myocardium.
abstract: S100A1, a Ca superset2+-binding protein of the EF-hand type, is preferentially expressed in myocardial tissue and has been shown to enhance cardiac contractile performance by regulating both sarcoplasmic reticulum (SR) Ca superset2+-handling and myofibrillar Ca superset2+-responsiveness. In cardiac disease, the expression of S100A1 is dynamically altered as it is significantly down-regulated in end stage human heart failure (HF), and it is up-regulated in compensated hypertrophy. Therefore, the delivery of a transgene encoding for S100A1 to the myocardium might be an attractive strategy for improving cardiac function in HF by replacing lost endogenous S100A1. In this study we sought to test whether exogenous S100A1 gene delivery to alter global cardiac function is feasible in the normal rabbit heart. An adenoviral S100A1 transgene (AdvS100A1) also containing the green fluorescent protein (GFP) was delivered using an intracoronary injection method with a dose of 5 x 10 superset11 total virus particles (tvp) (n = 8). Rabbits treated with either a GFP-only adenovirus (AdvGFP) or saline were used as control groups (n = 11 each). Seven days after global myocardial in vivo gene delivery hemodynamic parameters were assessed. S100A1 overexpression as a result of the intracoronary delivery of AdvS100A1 significantly increased left ventricular (LV) +dP/dt subsetmax, -dP/dt subsetmin and systolic ejection pressure (SEP) compared to both control groups after administration of isoproterenol (0.1, 0.5 and 1.0 microg/kgBW/min), while contractile parameters remained unchanged under basal conditions. These results demonstrate that global myocardial in vivo gene delivery is possible and that myocardial S100A1 overexpression can increase cardiac performance. Therefore, substitution of down-regulated S100A1 protein expression levels may represent a potential therapeutic strategy for improving the cardiac performance of the failing heart.
authors.affiliation: Department of Internal Medicine III, Division of Cardiology, University of Heidelberg, Otto-Meyerhof-Zentrum, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany. sven.pleger@jefferson.edu
authors.forename: S T
authors.initials: ST
authors.lastname: Pleger
authors.forename: P
authors.initials: P
authors.lastname: Most
authors.forename: B
authors.initials: B
authors.lastname: Heidt
authors.forename: M
authors.initials: M
authors.lastname: Voelkers
authors.forename: J A
authors.initials: JA
authors.lastname: Hata
authors.forename: H A
authors.initials: HA
authors.lastname: Katus
authors.forename: A
authors.initials: A
authors.lastname: Remppis
authors.forename: W J
authors.initials: WJ
authors.lastname: Koch
mesh_terms: D000256:Adenoviridae; D000818:Animals; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D049452:Green Fluorescent Proteins; D007267:Injections; D008297:Male; D009200:Myocardial Contraction / Q000235:genetics*; D009206:Myocardium / Q000378:metabolism*; D011817:Rabbits; D009418:S100 Proteins / Q000235:genetics* / Q000378:metabolism; D016277:Ventricular Function, Left
chemical_list: D009418:S100 Proteins; C110294:S100A1 protein; D049452:Green Fluorescent Proteins